CA2190752A1 - Facteurs de croissance proches de l'insuline modifies - Google Patents
Facteurs de croissance proches de l'insuline modifiesInfo
- Publication number
- CA2190752A1 CA2190752A1 CA002190752A CA2190752A CA2190752A1 CA 2190752 A1 CA2190752 A1 CA 2190752A1 CA 002190752 A CA002190752 A CA 002190752A CA 2190752 A CA2190752 A CA 2190752A CA 2190752 A1 CA2190752 A1 CA 2190752A1
- Authority
- CA
- Canada
- Prior art keywords
- igf
- peg
- mutein
- muteins
- conjugate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24827394A | 1994-05-24 | 1994-05-24 | |
| US08/248,273 | 1994-05-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2190752A1 true CA2190752A1 (fr) | 1995-11-30 |
Family
ID=22938406
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002190752A Abandoned CA2190752A1 (fr) | 1994-05-24 | 1995-05-24 | Facteurs de croissance proches de l'insuline modifies |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0756494A1 (fr) |
| JP (1) | JPH10500693A (fr) |
| AU (1) | AU2601895A (fr) |
| CA (1) | CA2190752A1 (fr) |
| WO (1) | WO1995032003A1 (fr) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| US7122636B1 (en) | 1997-02-21 | 2006-10-17 | Genentech, Inc. | Antibody fragment-polymer conjugates and uses of same |
| NZ336839A (en) | 1997-02-21 | 2001-08-31 | Genentech Inc | Antibody fragment-polymer conjugates and humanized anti-IL-8 monoclonal antibodies |
| US7270809B2 (en) | 1997-07-14 | 2007-09-18 | Bolder Biotechnology, Inc. | Cysteine variants of alpha interferon-2 |
| CN1269805A (zh) | 1997-07-14 | 2000-10-11 | 博尔德生物技术公司 | 生长激素和相关蛋白的衍生物 |
| US7153943B2 (en) | 1997-07-14 | 2006-12-26 | Bolder Biotechnology, Inc. | Derivatives of growth hormone and related proteins, and methods of use thereof |
| US6753165B1 (en) | 1999-01-14 | 2004-06-22 | Bolder Biotechnology, Inc. | Methods for making proteins containing free cysteine residues |
| US20080076706A1 (en) | 1997-07-14 | 2008-03-27 | Bolder Biotechnology, Inc. | Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof |
| US7495087B2 (en) | 1997-07-14 | 2009-02-24 | Bolder Biotechnology, Inc. | Cysteine muteins in the C-D loop of human interleukin-11 |
| US6468532B1 (en) | 1998-01-22 | 2002-10-22 | Genentech, Inc. | Methods of treating inflammatory diseases with anti-IL-8 antibody fragment-polymer conjugates |
| US7005504B2 (en) | 1998-01-22 | 2006-02-28 | Genentech, Inc. | Antibody fragment-peg conjugates |
| US6458355B1 (en) | 1998-01-22 | 2002-10-01 | Genentech, Inc. | Methods of treating inflammatory disease with anti-IL-8 antibody fragment-polymer conjugates |
| JP2002510646A (ja) | 1998-04-03 | 2002-04-09 | カイロン コーポレイション | 関節軟骨障害を処置するためのｉｇｆｉの使用 |
| JP2002534119A (ja) * | 1999-01-14 | 2002-10-15 | ボルダー バイオテクノロジー， インコーポレイテッド | 自由システイン残基を有するタンパク質の生産方法 |
| US8288126B2 (en) * | 1999-01-14 | 2012-10-16 | Bolder Biotechnology, Inc. | Methods for making proteins containing free cysteine residues |
| WO2000059926A1 (fr) * | 1999-04-02 | 2000-10-12 | Ajinomoto Co., Inc. | Procede de production de sous-unite de peptide issue d'une proteine de polymere |
| IL152804A0 (en) * | 2000-05-16 | 2003-06-24 | Bolder Biotechnology Inc | Methods for refolding proteins containing free cysteine residues |
| EP2382982A3 (fr) | 2001-08-24 | 2012-02-22 | Neuren Pharmaceuticals Limited | Peptides de régéneration neurale et procédés d'utilisation de ces derniers dans le traitement des lesions cerebrales |
| US8129330B2 (en) | 2002-09-30 | 2012-03-06 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof |
| CN102319437B (zh) | 2002-12-26 | 2017-10-13 | 山景医药公司 | 具有增强的生物学效用的干扰素‑β的聚合物缀合物 |
| EP1674113A1 (fr) * | 2004-12-22 | 2006-06-28 | F. Hoffmann-La Roche Ag | Conjugués de l'IGF-1 et du poly(éthylène glycol) |
| CN101268098A (zh) | 2005-08-30 | 2008-09-17 | 诺沃-诺迪斯克保健股份有限公司 | 聚乙二醇化生长激素的液体制剂 |
| US8329866B2 (en) | 2005-10-03 | 2012-12-11 | Bolder Biotechnology, Inc. | Long acting VEGF inhibitors and methods of use |
| US8343918B2 (en) | 2006-06-09 | 2013-01-01 | Novartis Ag | Stabilized insulin-like growth factor polypeptides |
| WO2008003750A2 (fr) | 2006-07-07 | 2008-01-10 | Novo Nordisk Health Care Ag | Nouveaux conjugués de protéines et leurs procédés de préparation |
| CL2007002502A1 (es) | 2006-08-31 | 2008-05-30 | Hoffmann La Roche | Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer. |
| CN101484469B (zh) | 2006-08-31 | 2012-12-12 | 弗·哈夫曼-拉罗切有限公司 | 生产胰岛素样生长因子-ⅰ的方法 |
| US8617531B2 (en) | 2006-12-14 | 2013-12-31 | Bolder Biotechnology, Inc. | Methods of making proteins and peptides containing a single free cysteine |
| ES2433568T3 (es) | 2007-10-17 | 2013-12-11 | Curonz Holdings Company Limited | Análogos sintéticos de péptidos de regeneración neuronal |
| AU2009231394B2 (en) * | 2008-04-03 | 2013-09-05 | F. Hoffmann-La Roche Ag | Use of PEGylated IGF-I variants for the treatment of neuromuscular disorders |
| US9587006B2 (en) * | 2010-02-11 | 2017-03-07 | Hoffmann-La Roche Inc. | IGF-I poly (ethylene glycol) conjugates |
| ES2674567T3 (es) | 2010-05-21 | 2018-07-02 | Merrimack Pharmaceuticals, Inc. | Proteínas de fusión biespecíficas |
| SI2667715T1 (sl) | 2011-01-27 | 2017-11-30 | Neuren Pharmaceuticals Limited | Zdravljenje motenj avtističnega spektra z uporabo glicil-l-2-metilprolil-l-glutaminske kisline |
| CA3000742A1 (fr) | 2015-10-02 | 2017-04-06 | Silver Creek Pharmaceuticals, Inc. | Proteines therapeutiques bispecifiques pour la reparation de tissus |
| EP3946413A4 (fr) * | 2019-04-03 | 2023-01-11 | Technical University of Denmark | Conjugués de protéine de facteur neurotrophique et modes de réalisation associés |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5166322A (en) * | 1989-04-21 | 1992-11-24 | Genetics Institute | Cysteine added variants of interleukin-3 and chemical modifications thereof |
| GEP20033082B (en) * | 1991-03-15 | 2003-10-27 | Amgen Inc | Pegylation of Polypeptides |
| EP0679095A1 (fr) * | 1992-11-25 | 1995-11-02 | Amgen Boulder Inc. | Facteur de croissance insulinoide modifie |
| CN1134111A (zh) * | 1993-04-07 | 1996-10-23 | 赛纳根公司 | 使用胰岛素样生长因子结合蛋白质的方法 |
-
1995
- 1995-05-24 WO PCT/US1995/006540 patent/WO1995032003A1/fr not_active Ceased
- 1995-05-24 AU AU26018/95A patent/AU2601895A/en not_active Abandoned
- 1995-05-24 CA CA002190752A patent/CA2190752A1/fr not_active Abandoned
- 1995-05-24 EP EP95920629A patent/EP0756494A1/fr not_active Withdrawn
- 1995-05-24 JP JP7530514A patent/JPH10500693A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP0756494A1 (fr) | 1997-02-05 |
| WO1995032003A1 (fr) | 1995-11-30 |
| AU2601895A (en) | 1995-12-18 |
| JPH10500693A (ja) | 1998-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH10500693A (ja) | 改変型インスリン様増殖因子 | |
| JP4949844B2 (ja) | エリスロポエチン受容体に結合する新規ペプチド | |
| EP0679095A1 (fr) | Facteur de croissance insulinoide modifie | |
| JP3820105B2 (ja) | Ｍｐ１受容体に結合し血小板生成活性を有する二量体トロンボポエチンペプチド模倣体 | |
| CA2191971C (fr) | Reactifs de couplage de derives de polyethyleneglycol et composes formes avec ces derniers | |
| JP5591691B2 (ja) | 生物活性を有する融合タンパク質を作製するための組成物及び方法 | |
| DE69529517T2 (de) | Kreisförmig permutierte liganden und kreisförmig permutierte chimärische molekülen | |
| KR970001563B1 (ko) | 재조합 슈도모나스 외독소, 이를 포함한 부작용이 낮은 활성 면역독소 및 이의 제조방법 | |
| JP4266028B2 (ja) | エリスロポエチン受容体に結合する新規ペプチド | |
| JP2541761B2 (ja) | ミュレル管抑制物質様ポリペプチドおよびその製造方法 | |
| PL202758B1 (pl) | Koniugat zawierający glikoproteinę erytropoetynę, kompozycja zawierająca te koniugaty, środek farmaceutyczny, zastosowanie tych koniugatów i tych kompozycji oraz sposób wytwarzania koniugatów erytropoetyny | |
| EP2917244B1 (fr) | Conjugués polypeptide dérivé d'aprotinine-anticorps | |
| JPH0829097B2 (ja) | 線維芽細胞発育因子 | |
| JP2022515229A (ja) | グルカゴン、ｇｌｐ－１及びｇｉｐ受容体の全てに活性を有する三重活性体と、インスリンとを含む薬学組成物 | |
| TW200529868A (en) | N-terminally monopegylated human growth hormone conjugates, process for their preparation, and methods of use thereof | |
| EP1122311A1 (fr) | Medicaments permettant de soigner la neuropathie contenant de la galectine-1 ou ses derives comme substance active | |
| JPH09503751A (ja) | 細胞毒性抱合体の単一起源性製剤 | |
| TWI643871B (zh) | 含有人類抗體κ型輕鏈複合體之組成物及其製造方法 | |
| US20040241800A1 (en) | Vascular endothelial growth factor dimers | |
| DE60313786T2 (de) | Poly(ethylen glykol)-konjugate von insulinähnlichem wachstumfaktor bindenden protein-4 | |
| US20160326501A1 (en) | Vegf antagonist compositions and uses thereof | |
| JP2006514984A (ja) | 癌療法で用いる修飾されたサイトカイン | |
| EP3049433B1 (fr) | Protéines de fusion constituées d'un facteur de stimulation des colonies granulocytaires avec d'autres partenaires de type facteur de croissance, de préférence avec un facteur de croissance de cellules souches, et leur procédé de préparation | |
| JP2018508580A (ja) | ペグ化ｉｌ−１１の組成物および方法 | |
| WO2004083242A1 (fr) | Conjugue de facteur stimulant les colonies de granulocytes humain presentant une stabilite accrue dans le sang et son procede de preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Dead |